Price
Target price
€23.60
€23.60
0.850%
0.2
0.850%
€42.64
15:10 / Tradegate
WKN: A1W2RM / Symbol: AGIO / Name: Agios / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Agios Pharmaceuticals Inc. Stock
The Agios Pharmaceuticals Inc. stock is trending slightly upwards today, with an increase of €0.20 (0.850%) compared to yesterday's price.
With 9 Buy predictions and only 1 Sell predictions the community sentiment for the stock is positive.
As a result the target price of 42 € shows a very positive potential of 77.97% compared to the current price of 23.6 € for Agios Pharmaceuticals Inc..
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Agios Pharmaceuticals Inc. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Agios Pharmaceuticals Inc. in the next few years
Pros
?
C******** o* t** e**********
?
M***** P*******
?
G***** c******* t* c**********
Cons
?
S********** s********
?
B****
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Agios Pharmaceuticals Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Agios Pharmaceuticals Inc. | 0.850% | 1.695% | -36.842% | -45.205% | -24.528% | -11.765% | -13.638% |
| Ironwood Pharmaceuticals | -2.550% | 0.641% | 46.729% | -10.795% | -25.238% | -71.640% | -68.122% |
| Novocure Ltd | -1.160% | 15.035% | 13.574% | -60.802% | -60.062% | -83.741% | -91.793% |
| Iovance Biotherapeutics Inc. | -1.160% | 1.443% | -16.260% | -76.601% | -72.311% | -70.837% | -95.364% |
Comments
Agios Pharmaceuticals (NASDAQ:AGIO) is now covered by analysts at Citigroup Inc.. They set a "buy" rating on the stock.
Show more
Ratings data for AGIO provided by MarketBeat
Agios Pharmaceuticals (NASDAQ:AGIO) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating on the stock.
Show more
Ratings data for AGIO provided by MarketBeat
Agios Pharmaceuticals (NASDAQ:AGIO) had its price target lowered by analysts at Bank of America Corporation from $54.00 to $32.00. They now have a "buy" rating on the stock.
Show more
Ratings data for AGIO provided by MarketBeat
News
Why Shares in Agios Pharmaceuticals Got Crushed Today
Shares in Agios Pharmaceuticals (NASDAQ: AGIO) crashed by 50% by noontime today. The move comes as the market digests a mixed set of topline results from its Phase 3 trial (RISE UP) of its sickle
Agios (AGIO) Q2 Revenue Jumps 45%
Agios Pharmaceuticals (NASDAQ:AGIO), a biotechnology company focused on therapies for rare blood disorders, released its second quarter 2025 earnings on July 31, 2025. The headline was a notable